A Charras1, E Smith1,2, C M Hedrich3,4,5. 1. Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK. 2. Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, UK. 3. Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK. christian.hedrich@liverpool.ac.uk. 4. Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, UK. christian.hedrich@liverpool.ac.uk. 5. Institute in the Park, Alder Hey Children's NHS Foundation Trust Hospital, East Prescot Road, Liverpool, L14 5AB, UK. christian.hedrich@liverpool.ac.uk.
Abstract
PURPOSE OF REVIEW: Juvenile-onset systemic lupus erythematosus ((j)SLE) is an autoimmune/inflammatory disease that results in significant damage and disability. When compared to patients with disease onset in adulthood, jSLE patients exhibit increased disease activity, damage and require more aggressive treatments. This manuscript summarises age-specific pathogenic mechanisms and underscores the need for age group-specific research, classification and treatment. RECENT FINDINGS: Genetic factors play a significant role in the pathophysiology of jSLE, as > 7% of patients develop disease as a result of single gene mutations. Remaining patients carry genetic variants that are necessary for disease development, but require additional factors. Increased 'genetic impact' likely contributes to earlier disease onset and more severe phenotypes. Epigenetic events have only recently started to be addressed in jSLE, and add to the list of pathogenic mechanisms that may serve as biomarkers and/or treatment targets. To allow meaningful and patient-oriented paediatric research, age-specific classification criteria and treatment targets require to be defined as currently available tools established for adult-onset SLE have limitations in the paediatric cohort. Significant progress has been made in understanding the pathophysiology of jSLE. Meaningful laboratory and clinical research can only be performed using age group-specific tools, classification criteria and treatment targets.
PURPOSE OF REVIEW: Juvenile-onset systemic lupus erythematosus ((j)SLE) is an autoimmune/inflammatory disease that results in significant damage and disability. When compared to patients with disease onset in adulthood, jSLE patients exhibit increased disease activity, damage and require more aggressive treatments. This manuscript summarises age-specific pathogenic mechanisms and underscores the need for age group-specific research, classification and treatment. RECENT FINDINGS: Genetic factors play a significant role in the pathophysiology of jSLE, as > 7% of patients develop disease as a result of single gene mutations. Remaining patients carry genetic variants that are necessary for disease development, but require additional factors. Increased 'genetic impact' likely contributes to earlier disease onset and more severe phenotypes. Epigenetic events have only recently started to be addressed in jSLE, and add to the list of pathogenic mechanisms that may serve as biomarkers and/or treatment targets. To allow meaningful and patient-oriented paediatric research, age-specific classification criteria and treatment targets require to be defined as currently available tools established for adult-onset SLE have limitations in the paediatric cohort. Significant progress has been made in understanding the pathophysiology of jSLE. Meaningful laboratory and clinical research can only be performed using age group-specific tools, classification criteria and treatment targets.
Authors: Linda T Hiraki; Candace H Feldman; Jun Liu; Graciela S Alarcón; Michael A Fischer; Wolfgang C Winkelmayer; Karen H Costenbader Journal: Arthritis Rheum Date: 2012-08
Authors: Eve Mary Dorothy Smith; Hanna Lythgoe; Angela Midgley; Michael William Beresford; Christian Michael Hedrich Journal: Clin Immunol Date: 2019-10-31 Impact factor: 3.969
Authors: Frances Rees; Michael Doherty; Matthew Grainge; Graham Davenport; Peter Lanyon; Weiya Zhang Journal: Ann Rheum Dis Date: 2014-09-29 Impact factor: 19.103
Authors: Samar A Soliman; Anam Haque; Kamala Vanarsa; Ting Zhang; Faten Ismail; Kyung Hyun Lee; Claudia Pedroza; Larry A Greenbaum; Sherene Mason; M John Hicks; Scott E Wenderfer; Chandra Mohan Journal: Front Immunol Date: 2022-05-26 Impact factor: 8.786